Dr. Dana King Begins New Clinical Trial on Pioglitazone to Reduce Cardiovascular Risk in Diabetes
From the Dept. of Family Medicine, Dr. Dana King is beginning a new trial on the effect of pioglitazone on ADMA levels. ADMA -- asymmetric dimethylarginine --is a chemical in the blood that is a risk factor for cardiovascular disease. It is often elevated in overweight diabetic patients. High ADMA levels approximately double the risk of heart disease in diabetic patients.
It is speculated that piagidazone may reduce ADMA levels and thereby reduce risk for heart disease. Pioglitazone, (brand name Actos), is an already approved medication that increases the body’s sensitivity to insulin. This study seeks to determine if there is an additional benefit to this medication for patients with diabetes. The study will involve 36 patients who will serve as their own controls in the study. Patients will have a one month washout and will then be randomized to receive pioglitazone or placebo.